Literature DB >> 2069564

Phosphoramidon inhibits the conversion of intracisternally administered big endothelin-1 to endothelin-1.

H Shinyama1, T Uchida, H Kido, K Hayashi, M Watanabe, Y Matsumura, R Ikegawa, M Takaoka, S Morimoto.   

Abstract

It is suggested that endothelin-1 (ET-1), a potent vasoconstrictor peptide, is involved in the pathogenesis of cerebral vasospasm following subarachnoid hemorrhage (SAH). We examined the effects of intracisternal administration of big ET-1 on the cerebral arteries in the absence or presence of pretreatment with phosphoramidon, an inhibitor of ET converting enzyme, in anesthetized dogs. After intracisternal administration of big ET-1 (10 micrograms/dog), the caliber of the basilar artery on the angiogram was decreased to about 59% of the control. This was accompanied by a marked increase in immunoreactive ET in the cerebrospinal fluid. Systemic arterial pressure was markedly elevated following big ET-1 injection. All changes induced by big ET-1 were effectively prevented with phosphoramidon. These data suggest that intracisternally administered big ET-1 is converted to ET-1 and that the generated ET-1 produces cerebral vasospasm and hypertension. A phosphoramidon-sensitive metalloproteinase appears to contribute to this conversion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069564     DOI: 10.1016/0006-291x(91)91774-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Regional differences in endothelin converting enzyme activity in rat brain: inhibition by phosphoramidon and EDTA.

Authors:  T D Warner; G P Budzik; T Matsumoto; J A Mitchell; U Förstermann; F Murad
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.